Company to present at Animal Longevity Summit 2026
Genflow Biosciences Plc has been invited to present data from its SLAB clinical study, evaluating its SIRT6 gene therapy for age-related decline in companion animals, at the Animal Longevity Summit in Toronto on October 1-2, 2026. This presentation is expected to provide comprehensive data from the company's veterinary longevity program, aligning with its strategy to develop therapies for aging mechanisms with potential applications in both veterinary and human health. The SLAB study, which began in March 2025 and concludes in June 2026, assesses the safety and biological activity of Genflow's proprietary SIRT6 centenarian gene therapy in aged beagles.
Select text to share a quote on X · sign in to keep highlights & notes in your GENF notes
Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, today announces that it has been invited to present data from its SLAB (Sarcopenia and Longevity in Aged Beagles) clinical study at the Animal Longevity Summit ("ALOS"), taking place in Toronto, Canada, on 1-2 October 2026.
The SLAB study is designed to evaluate the potential of Genflow's centenarian SIRT6 gene therapy to address multiple hallmarks of aging and age-related decline in companion animals. The presentation is expected to provide one of the most comprehensive datasets generated to date from the Company's veterinary longevity programme and forms part of Genflow's broader strategy to develop therapies targeting fundamental biological mechanisms associated with aging, with applications in both veterinary and human health.
ALOS is the first conference dedicated exclusively to animal longevity and is expected to bring together leading researchers, veterinary scientists, biotechnology companies, and investors focused on extending healthy lifespan in companion animals. Confirmed speakers include Dr. Matt Kaeberlein, Dr. Vera Gorbunova, Dr. Aubrey de Grey, Liz Parrish, Dr. Noah Davidsohn, and Dr. Varun Dwaraka.
Further details regarding the presentation schedule will be announced by the conference organisers.
- Eric Leire, Chief Executive Officer of Genflow, commented: "We are pleased to have been invited to present our SLAB study findings at the Animal Longevity Summit, a leading forum dedicated to advancing the science of healthy aging in companion animals. The study represents an important step in evaluating the potential of our proprietary centenarian SIRT6 gene therapy approach in a real-world aging model. We look forward to sharing the data with researchers, veterinarians, industry participants and investors focused on the emerging longevity sector."
About the SLAB Study
The SLAB (Sarcopenia and Longevity in Aged Beagles) study is evaluating the safety and biological activity of Genflow's proprietary SIRT6 centenarian gene therapy in aged beagles. The study began in March 2025 and ends in June 2026.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.